HIV-VAC, Inc. Issues S-8 Stock

HIV-VAC, Inc. Issues S-8 Stock

Business Wire - November 11, 2002

TORONTO--(BUSINESS WIRE)--Nov. 11, 2002--HIV-VAC INC. (the "Company") announces that it filed a Form S-8 Registration Statement with the SEC in connection with the issuance of an aggregate of 1,150,000 common shares on October 30, 2002. The shares were issued to a total of four consultants who each provided business consulting services to HIV-VAC, Inc.

The consulting services provided by the consultants assisted the company in developing a new business plan, updating and enhancing the company's web-site, and creating new presentation tools.

HIV-VAC, Inc. is developing the Skinner HIV-VAC AIDS vaccine which is based on a unique approach to neutralizing the AIDS virus. Unlike many other AIDS vaccines under development, the Company believes that the Skinner vaccine has the potential to be effective with the AIDS virus' many mutant forms. This technology is based on a unique intracellular vaccine technology proven in clinical trials with herpes genitalis and pre-clinical research into cytomegalovirus and equine herpes vaccines. This vaccine was originally developed by Dr. Skinner and his team at the University of Birmingham, United Kingdom.

The statements contained in this release which are not historical facts contain forward-looking information with respect to plans, projections or future performance of the company; the occurrence of which involves certain risks and uncertainties that could cause the company's actual results to differ materially from expected results. Such risks include the timing of implementation and the scope and success of the program described here.

CONTACT: HIV-VAC, Inc.

Kevin Murray, 705/444-6317

http://www.hivvac.com /

SOURCE: HIV-VAC, Inc.

021111
BW021106

Copyright © 2002 - Business Wire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Business Wire, Permissions Desk, Business Wire, 1185 Avenue of the Americas, 3rd Floor, New York, NY 10036; Tel: (212) 575-8822; FAX: (212) 575-1854. http://www.businesswire.com.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.

Always watch for outdated information. This article first appeared in 2002. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2002. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .